Long‐term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co‐infected Chinese

The aim of this retrospective study was to observe hepatitis B surface antigen (HBsAg) seroclearance and explore predictors of HBsAg loss in HIV/HBV‐co‐infected patients receiving long‐term lamivudine or both tenofovir and lamivudine containing therapies. Quantification of HBsAg, hepatitis B e antigen and HBV DNA before and after initiation of HBV‐active antiretroviral therapy in a total of 268 HIV/HBV‐co‐infected patients started treatment between 2005 and 2017 were performed. Over a median of 65.63 months of follow‐up, 10 (3.7%) were observed HBsAg loss and the quantification of HBsAg in 7 (2.6%) patients were less than 50 IU/mL. With the prolongation of antiretroviral therapy duration time, the rates of HBsAg seroclearance tended to increase gradually, rising from 1.8% (3/163) during 2‐4 years treatment to 29.4% (10/34) after antiretroviral therapy for up to 10 years. Lower baseline qHBsAg and HBV DNA levels and strong 12‐month declines in qHBsAg were significantly associated with HBsAg seroclearance. The event of HBsAg seroclearance is uncommon among Chinese individuals with HIV/HBV co‐infection who have been treated with anti‐HBV containing antiretroviral therapy, and lifelong therapy for HBV is needed for HIV/HBV co‐infected patients. Baseline qHBsAg and HBV DNA levels and qHBsAg decline rate were predictors for HBsAg seroclearance.

[1]  Hsin-Yun Sun,et al.  Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[2]  T. Harrison,et al.  High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China , 2018, Intervirology.

[3]  C. Delaugerre,et al.  Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa , 2018, Journal of viral hepatitis.

[4]  C. Delaugerre,et al.  Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. , 2016, Journal of hepatology.

[5]  Q. Cao,et al.  Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates , 2016, BMC Infectious Diseases.

[6]  C. Thio,et al.  Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL , 2016, Journal of acquired immune deficiency syndromes.

[7]  C. Delaugerre,et al.  Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV‐hepatitis B virus coinfected patients from Sub‐Saharan Africa , 2016, Journal of gastroenterology and hepatology.

[8]  F. Zoulim,et al.  Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus , 2015, AIDS.

[9]  G. Gao,et al.  Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China , 2015, PloS one.

[10]  H. Chan,et al.  Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. , 2015, Journal of hepatology.

[11]  C. Delaugerre,et al.  Use of hepatitis B surface and “e” antigen quantification during extensive treatment with tenofovir in patients co‐infected with HIV‐HBV , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[12]  M. Tsai,et al.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. , 2014, World Journal of Gastroenterology.

[13]  C. Delaugerre,et al.  Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications , 2014, Hepatology.

[14]  A. Rieger,et al.  Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV‐/HBV‐coinfected patients , 2014, Journal of viral hepatitis.

[15]  S. Lewin,et al.  Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals , 2013, PloS one.

[16]  E. Boyko,et al.  The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection , 2013, Hepatology.

[17]  R. D. de Man,et al.  Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. , 2012, The Journal of infectious diseases.

[18]  C. Delaugerre,et al.  Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients , 2012, AIDS.

[19]  R. Monina Klevens,et al.  The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.

[20]  M. Yuen,et al.  Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment , 2011, The American Journal of Gastroenterology.

[21]  V. Wong,et al.  Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. , 2011, The Journal of infectious diseases.

[22]  S. Ahn,et al.  Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir , 2011, Hepatology.

[23]  M. Manns,et al.  Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients , 2010, Hepatology.

[24]  S. Lewin,et al.  Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers , 2010, Hepatology.

[25]  Xia-qiu Zhou,et al.  On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[26]  R. D. de Man,et al.  Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B * , 2010, Journal of viral hepatitis.

[27]  P. Marcellin,et al.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.

[28]  S. Lewin,et al.  Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection , 2009, Journal of Virology.

[29]  Chien-Jen Chen,et al.  Hepatitis B virus DNA levels and outcomes in chronic hepatitis B , 2009, Hepatology.

[30]  P. Marcellin,et al.  Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.

[31]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[32]  Gui Xi-en,et al.  Interaction of hepatitis B and C viruses in patients infected with HIV. , 2008, Journal of acquired immune deficiency syndromes.

[33]  M. Chevallier,et al.  Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.